According to a new report by Polaris Market Research, the global drug discovery services market was valued at USD 22.04 billion in 2025 and is projected to reach USD 75.13 billion by 2034, expanding at a CAGR of 14.6% over the forecast period. Growth is underpinned by rising complexity of drug discovery processes, expanding outsourcing of research activities, and accelerating adoption of AI-enabled discovery platforms across key therapeutic areas.

What Is Driving Drug Discovery Services Market Growth?

Demand is climbing as pharmaceutical and biotech companies increasingly outsource research to contain costs and access specialized platforms. Sponsors are prioritizing high-throughput screening and advanced cell models, pushing drug discovery services adoption across oncology and biologics programs. Polaris analysts note that a 2024 Association of Clinical Research Organizations report found outsourcing can accelerate drug development by 30%, positioning the target selection segment for sustained growth through 2034, with pharmaceutical & biotechnology companies emerging as the largest end-user contributor and biology services posting the fastest incremental gains.

Key Trends Shaping the Drug Discovery Services Industry

AI-Enabled Target Identification and Screening

Artificial intelligence continues to compress discovery timelines. AI platforms now support target identification through genomic, proteomic, and clinical data analysis, while machine learning models predict compound-toxicity interactions to reduce trial-and-error in preclinical research — a 2023 study in Nature Reviews Drug Discovery found AI-assisted discovery services can cut costs by as much as 20%.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/drug-discovery-services-market

Expansion of Gene Therapy Discovery Capabilities

Providers are scaling capacity for increasingly complex biologics programs. In November 2024, Charles River Laboratories announced the expansion of its gene therapy capabilities through a new facility acquisition, reflecting the biology-driven services segment's rapid growth as biologics and personalized medicines advance.

Digital and Decentralized Trial Integration

Discovery service providers are extending capabilities closer to clinical development. In September 2024, Covance expanded its digital and decentralized clinical trial capabilities to streamline drug development processes and improve patient engagement, illustrating the industry trend toward more fully integrated discovery-to-development service models.

Market Segmentation: Breaking Down the Drug Discovery Services Market

Polaris segments the drug discovery services market by process, type, drug type, therapeutic area, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Process

Target selection leads the market given its crucial role in identifying and validating biological targets with the highest likelihood of medical significance. Lead optimization is registering the fastest growth, supported by predictive ADME/Tox modeling and design-make-test cycles that improve compound safety and pharmacokinetics ahead of clinical trials.

By Type

Chemistry services currently hold the largest share, reflecting their pivotal role in medicinal, synthetic, and analytical chemistry for drug candidate synthesis. Biology services are registering the highest growth rate as biologics, monoclonal antibodies, and gene therapies advance, supported by CRISPR and next-generation sequencing integration.

By Drug Type

Small molecule discovery services remain dependent on strong medicinal chemistry and high-throughput approaches, while biologics-driven discovery is increasingly based on biology-centric platforms, advanced cell models, and disease-mechanism validation — a shift reshaping CRO service mix industry-wide.

By Therapeutic Area

Oncology remains the leading therapeutic area, driven by active development pipelines and novel targets in solid tumors and hematological malignancies. Cardiovascular-metabolic, CNS, infectious disease, and rare disease categories are increasingly supported by specialized outsourcing models with disease-specific assays and biomarker strategies.

Regional Outlook: Where Is Drug Discovery Services Demand Growing Fastest?

North America holds the largest market share, mainly due to the well-established pharmaceutical industry, substantial R&D investment, and presence of major service providers, with the U.S. leading on infrastructure, government support, and early adoption of AI-enabled discovery platforms. Asia Pacific is witnessing rapid growth, driven by increasing investments in healthcare infrastructure and rising outsourcing to China and India. Within Asia Pacific, India's role is growing in chemistry services and integrated discovery support, while China's ecosystem is facilitating large-scale biological research; within Europe, Germany, the UK, and France benefit from strong government R&D support and academic-industry collaboration.

Competitive Landscape: Leading Drug Discovery Services Companies

Key players profiled in the report include Charles River Laboratories International, Inc., Covance Inc. (part of Labcorp), ICON plc, Syngene International Ltd., WuXi AppTec Co., Ltd., and Evotec SE, who are focusing on consolidation, AI-enabled discovery workflows, and modality-specific expertise to strengthen market position across the target selection and pharmaceutical & biotechnology company segments outlined above. Recent moves include Charles River's November 2024 gene therapy facility expansion and Covance's September 2024 digital and decentralized trial capability expansion, both aimed at deepening integrated discovery-to-development share.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching outsourced discovery capacity, this report benchmarks drug discovery services market share, segment-level pricing, and forecast data — by process, type, therapeutic area, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing CRO vendors, investors sizing entry points in biologics discovery, and strategy teams tracking biology services as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

animal-feed-market

graphite-market

experience-travel-services-market

functional-water-benefits-types-market

lithium-ion-battery-market

europe-chemical-distribution-market

adventure-tourism-market

profiling-top-10-firms-in-the-connected-cars-market-2025

ot-firewall-market